Why Attend the 2nd Protein Degradation for CNS Summit?
The Protein Degradation for CNS Summit is returning for a 2nd year with a focus on discussing the industry’s key challenges from designing degraders capable of crossing the BBB, exploring the best strategies for optimising dosage and distribution of drugs to translating in vivo studies into drugs approved for Phase I clinical trials. This is your comprehensive guide to translating protein degrader therapies to clinic.
Hear the latest developments from a range of Biopharma, including Biogen, Monte Rosa Therapeutics and Sanofi to AUTOTAC Bio and Arvinas. Understand the current findings in degrader design methodologies and the novel mechanisms and targets being explored for therapy development to aid future progress in the development of effective of drugs for treating neurodegenerative disease.
Join the Summit to:
Delve into the translational processes required to advance protein degradation drugs for CNS diseases to clinic as preclinical success brings more biotech and pharma companies closer than ever, making this focus imperative. Hear from industry leading experts, including Arvinas, AUTOTAC Bio and Sanofi on bridging this gap and progressing through trials
Explore the latest results from studies investigating the mechanisms for successful protein degradation within the brain, be informed on the most recent findings to aid drug discovery for neurodegenerative disease with Biogen and Captor Therapeutics
Gain insight into the most cutting edge approaches of designing protein degraders from development of libraries and high-throughput screening techniques to AI modelling of degrader molecules with UbiquiTX
Understand the current methodologies for solving the unique pharmacokinetic challenges within the brain and how to optimise drug development for these consideration with Harvard University
Examine the advancements in techniques, strategies and approaches from a range of companies and research groups including Sybilla and Draupnit Bio as they lead case studies and share results from newly published papers on protein degradation for neurodegenerative disease
Who Will You Meet?
80+ neuroscientists, structural and chemical biologists, medicinal chemists, pharmacologists and protein degrader experts from the leading biotechnology and pharmaceutical companies in the industry.
What Your Peers Have to Say
“Very dense program, great lineup of speakers, focused discussions.”
Monte Rosa Therapeutics
"I am looking forward to meeting other TPD enthusiasts. By working together, we can progress novel modalities against devastating neurological disorders."
Associate Principal Scientist, Merck
“This meeting provides a wonderful opportunity for leaders in this field to share ideas.”
Harvard University
Download the Full Event Guide for more information on:
- 20+ Biotech & Pharma Speakers
- 4 Interactive Deep-Dive Workshops
- 6+ Hours of Networking
- & Much More!
